按需从PEDOT/SNP复合物进行电控的perampanel供应,用于控制发作
Ying Zhu1, Siwei Li1, Zhemeng Wang2
1Beijing Institute of Basic Medical Sciences, Beijing, 100850, China. sisun819@outlook.com.
Journal of materials chemistry. B
|March 28, 2025
概括
这项研究开发了一种新型的神经电极,通过将导电聚合物与含药纳米粒子进行兴奋剂. 这增强了电气特性,并使按需药物输送成为可能,以改善治疗.
科学领域:
- 生物医学工程 生物医学工程
- 神经科学是一个神经科学.
- 材料科学 材料科学 材料科学
背景情况:
- 药物耐药性的治疗通常涉及神经调节技术,如深度大脑刺激.
- 优化神经电极对于有效的控制和神经活动调节至关重要.
- 目前的方法在精确控制和药物输送整合方面存在局限性.
研究的目的:
- 为了提高治疗的神经电极性能.
- 开发一种与电刺激集成的按需药物输送方法.
- 为了提高神经调节神经系统疾病的疗效.
主要方法:
- 合成的硫化纳米颗粒 (SNPs) 装有抗发作药物perampanel.
- 在合金电极上的电化学沉积PEDOT/SNP-perampanel复合物.
- 评估电化学特性 (电荷储存能力,阻抗) 和药物释放动力学.
主要成果:
- 修改后的电极显示电荷储存容量显著增加.
- 在1kHz的电化学阻抗大大降低,提高了电极性能.
- 在需求时通过电刺激成功触发了对帕拉曼内尔的释放.
- 对精确的,局部的药物输送有明显的潜力,以减少发作的频率.
结论:
- PEDOT/SNP-perampanel修改增强了神经电极功能,用于治疗.
- 这种方法可以实现精确的,电触发的药物输送,改善治疗结果.
- 开发的方法对先进的神经接口和治疗神经疾病充满希望.
相关概念视频
Antiepileptic Drugs: Sodium Channel Blockers
Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Antiepileptic Drugs: Potassium Channel Activators
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
Modified-Release Drug Delivery Systems: Rate-Programmed II
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
Modified-Release Drug Delivery Systems: Rate-Programmed I
Rate-programmed drug delivery systems (DDS) are designed to release drugs at specific, controlled rates to maintain consistent therapeutic levels. These systems are categorized based on their release mechanisms, including dissolution-controlled DDS, diffusion-controlled DDS, and combined dissolution-diffusion-controlled DDS.In dissolution-controlled DDS, the release rate depends on the slow dissolution of the drug itself or the surrounding matrix. Drugs with inherently slow dissolution rates,...
Modified-Release Drug Delivery Systems: Stimuli-Activated
Stimuli-activated drug delivery systems are designed to release drugs in response to specific physical, chemical, or biological stimuli. These systems often utilize hydrogels—three-dimensional, hydrophilic polymer networks capable of swelling in aqueous environments and retaining significant fluid volumes. Upon exposure to particular stimuli, these hydrogels undergo structural transitions that allow the embedded drug to be released. Due to this adaptive behavior, such systems are also called...


